ALUISIO AUGUSTO COTRIM SEGURADO
Projetos de Pesquisa
Unidades Organizacionais
Departamento de Moléstias Infecciosas e Parasitárias, Faculdade de Medicina - Docente
LIM/49 - Laboratório de Protozoologia, Hospital das Clínicas, Faculdade de Medicina - Líder
LIM/49 - Laboratório de Protozoologia, Hospital das Clínicas, Faculdade de Medicina - Líder
3 resultados
Resultados de Busca
Agora exibindo 1 - 3 de 3
- Study protocol for the multicentre cohorts of Zika virus infection in pregnant women, infants, and acute clinical cases in Latin America and the Caribbean: the ZIKAlliance consortium(2019) AVELINO-SILVA, Vivian I.; MAYAUD, Philippe; TAMI, Adriana; MIRANDA, Maria C.; ROSENBERGER, Kerstin D.; ALEXANDER, Neal; NACUL, Luis; SEGURADO, Aluisio; POHL, Moritz; BETHENCOURT, Sarah; VILLAR, Luis A.; VIANA, Isabelle F. T.; RABELLO, Renata; SORIA, Carmen; SALGADO, Silvia P.; GOTUZZO, Eduardo; GUZMAN, Maria G.; MARTINEZ, Pedro A.; LOPEZ-GATELL, Hugo; HEGEWISCH-TAYLOR, Jennifer; BORJA-ABURTO, Victor H.; GONZALEZ, Cesar; NETTO, Eduardo M.; VILLARROEL, Paola M. Saba; HOEN, Bruno; BRASIL, Patricia; MARQUES, Ernesto T. A.; ROCKX, Barry; KOOPMANS, Marion; LAMBALLERIE, Xavier de; JAENISCH, Thomas; JAENISCH, Thomas; ROSENBERGER, Kerstin Daniela; MORALES, Ivonne; TOBIAN, Frank; UHLMANN, Lorenz; POHL, Moritz; SCHRETZMANN, Julius; LEEGE, Annika; MARQUES, Ernesto T. A.; MARQUES, Ernesto T. A.; VIANA, Isabelle F. T.; LINS, Roberto D.; FILIPPIS, Ana Maria Bispo de; DUARTE, Ana Claudia Machado; ESPINDOLA, Otavio de Melo; BONALDO, Myrna; RABELLO, Renata; DAMASCENO, Luana; MENDES-CORREA, Maria Cassia; MAYAUD, Philippe; NACUL, Luis; ALEXANDER, Neal; NETTO, Eduardo Martins; TAMI, Adriana; BETHENCOURT, Sarah; TINEDO, Maria Jose; ROSA, Yenifer La; MURILLO, Marianela; VILLAR, Luis Angel; MIRANDA, Maria Consuelo; LOZANO, Anyela; HERRERA, Victor Mauricio; GOMEZ, Adriana; GELVEZ, Rosa Margarita; ORTIZ, Ricardo; HERRERA, Victor Mauricio; SORIA, Carmen; DIMITRAKIS, Lady; SALGADO, Silvia Paola; ARRATA, Mary Regato; GOTUZZO, Eduardo; ALLISON, Humberto Guerra; TALLEDO, Michael; VILLARROEL, Paola Mariela Saba; TORRES, Eric Martinez; GUZMAN, Maria G.; RODRIGUEZ, Pedro A. Martinez; VERA, Mayling Alvarez; SANTANA, Belkis Galindo; REYES, Alicia; ALVAREZ, Silvia Serrano; DORTICOS, Diana Ferriol; HEGEWISCH-TAYLOR, Jennifer; ALPUCHE-ARANDA, Celia; LOPEZ-GATELL, Hugo; GONZALEZ-DIAZ, Esteban; PAVIA-RUZ, Norma; BORJA-ABURTO, Victor Hugo; GONZALEZ, Cesar; GRAJALES, Concepcion; ROJAS, Teresita; ARRIAGA, Lumumba; VALLEJOS, Alfonso; TYNEVEZ, Dominique; THIRION, Laurence; DREXLER, Jan Felix; ROCKX, Barry; GORP, Eric van; KOOPMANS, MarionBackground: The European Commission (EC) Horizon 2020 (H2020)-funded ZIKAlliance Consortium designed a multicentre study including pregnant women (PW), children (CH) and natural history (NH) cohorts. Clinical sites were selected over a wide geographic range within Latin America and the Caribbean, taking into account the dynamic course of the ZIKV epidemic. Methods: Recruitment to the PW cohort will take place in antenatal care clinics. PW will be enrolled regardless of symptoms and followed over the course of pregnancy, approximately every 4 weeks. PW will be revisited at delivery (or after miscarriage/abortion) to assess birth outcomes, including microcephaly and other congenital abnormalities according to the evolving definition of congenital Zika syndrome (CZS). After birth, children will be followed for 2 years in the CH cohort. Follow-up visits are scheduled at ages 1-3, 4-6, 12, and 24 months to assess neurocognitive and developmental milestones. In addition, a NH cohort for the characterization of symptomatic rash/fever illness was designed, including follow-up to capture persisting health problems. Blood, urine, and other biological materials will be collected, and tested for ZIKV and other relevant arboviral diseases (dengue, chikungunya, yellow fever) using RT-PCR or serological methods. A virtual, decentralized biobank will be created. Reciprocal clinical monitoring has been established between partner sites. Substudies of ZIKV seroprevalence, transmission clustering, disabilities and health economics, viral kinetics, the potential role of antibody enhancement, and co-infections will be linked to the cohort studies. Discussion: Results of these large cohort studies will provide better risk estimates for birth defects and other developmental abnormalities associated with ZIKV infection including possible co-factors for the variability of risk estimates between other countries and regions. Additional outcomes include incidence and transmission estimates of ZIKV during and after pregnancy, characterization of short and long-term clinical course following infection and viral kinetics of ZIKV.
- Validation of CD4(+) T-cell and viral load data from the HIV-Brazil Cohort Study using secondary system data(2018) CASSENOTE, Alex Jones Flores; GRANGEIRO, Alexandre; ESCUDER, Maria Mercedes; ABE, Jair Minoro; SEGURADO, Aluisio Augusto CotrimBackgroundThe HIV-Brazil Cohort Study (HIV-BCS) is a research primarily based on data collection from medical records of people living with HIV/AIDS in Brazil. The aim of this study was to present the validating design and results for the laboratory biomarkers viral load and CD4+ T-cell count from the HIV-Brazil Cohort Study.MethodsA total of 8007 patients who were started cART from 2003 to 2013 were considered eligible for this study. Total follow-up time was 32,397years. The median duration of follow-up was 3.51years (interquartile range - IQR 1.63-6.13years; maximum 11.51years). We used secondary data from the Brazilian Laboratory Tests Control System (SISCEL). Incidence of lab testing rates per 100 person years (100 py) were used to compare the number of laboratory tests carried out among cohort sites considering different databases for CD4+ T-cell counts and HIV viral load assessments. Descriptive statistics including 95% confidence interval, Pearson correlation coefficient, Bland-Altman agreement analysis and kappa coefficient agreement were applied for analysis.ResultsA total of 80,302 CD4+ T-cell counts and 79,997 HIV viral load assessments were observed in HIV-BCS versus 94,083 CD4+ T-cell counts and 84,810 viral loads from the Brazilian Laboratory Tests Control System. The general CD4+ T-cell HIV-BCS testing rate was 247 per 100 py versus 290 per 100 py and the viral load HIV-BCS testing rate was 246 per 100 py versus 261 per 100 py. The general correlation observed for the lowest quantitative CD4+ T-cell count before cART was 0.970 (p<0.001) and for the log of the highest viral load before cART was 0.971 (p<0.001). The general agreement coefficient for categorized CD4+ T-cell count was 0.932 (p<0.001) and for viral load was 0.996 (p<0.001).ConclusionsThe current study confirms that biomarkers CD4(+) T-cell count and viral load from the HIV-BCS have a high correlation and agreement with data from SISCEL, rendering both databases reliable and useful for epidemiological studies on HIV care in Brazil.
- Lack of evidence to support the association of a single IL28B genotype SNP rs12979860 with the HTLV-1 clinical outcomes and proviral load(2012) SANABANI, Sabri Saeed; NUKUI, Youko; PEREIRA, Juliana; COSTA, Antonio Charlys da; OLIVEIRA, Ana Carolina Soares de; PESSOA, Rodrigo; LEAL, Fabio Eudes; SEGURADO, Aluisio C.; KALLAS, Esper Georges; SABINO, Ester CerdeiraBackground: The Interleukin 28B (IL28B) rs12979860 polymorphisms was recently reported to be associated with the human T-cell leukemia virus type 1 (HTLV-1) proviral load (PvL) and the development of the HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP). Methods: In an attempt to examine this hypothesis, we assessed the association of the rs12979860 genotypes with HTLV-1 PvL levels and clinical status in 112 unrelated Brazilian subjects (81 HTLV-1 asymptomatic carriers, 24 individuals with HAM/TSP and 7 with Adult T cell Leukemia/Lymphoma (ATLL)). Results: All 112 samples were successfully genotyped and their PvLs compared. Neither the homozygote TT nor the heterozygote CT mutations nor the combination genotypes (TT/CT) were associated with a greater PvL. We also observed no significant difference in allele distribution between asymptomatic carriers and patients with HTLV-1 associated HAM/TSP. Conclusions: Our study failed to support the previously reported positive association between the IL28B rs12979860 polymorphisms and an increased risk of developing HAM/TSP in the Brazilian population.